Argos Therapeutics (ARGS) Earns Daily Media Impact Rating of 0.20

Media headlines about Argos Therapeutics (NASDAQ:ARGS) have trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Argos Therapeutics earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.6507087658362 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

Argos Therapeutics (ARGS) opened at $0.15 on Thursday. Argos Therapeutics has a 52-week low of $0.13 and a 52-week high of $5.68. The company has a current ratio of 2.29, a quick ratio of 2.29 and a debt-to-equity ratio of -1.46.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/12/21/argos-therapeutics-args-earns-daily-media-impact-rating-of-0-20.html.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Insider Buying and Selling by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit